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Vascular endothelial growth factors (VEGFs) and their receptors
(VEGFRs) are key drivers of blood and lymph vessel formation in
development, but also in several pathological processes. VEGF-C
signaling through VEGFR-3 promotes lymphangiogenesis, which is
a clinically relevant target for treating lymphatic insufﬁciency and
for blocking tumor angiogenesis and metastasis. The extracellular
domain of VEGFRs consists of seven Ig homology domains;
domains 1–3 (D1-3) are responsible for ligand binding, and the
membrane-proximal domains 4–7 (D4-7) are involved in structural
rearrangements essential for receptor dimerization and activation.
Here we analyzed the crystal structures of VEGF-C in complex with
VEGFR-3 domains D1-2 and of the VEGFR-3 D4-5 homodimer. The
structures revealed a conserved ligand-binding interface in D2 and
a unique mechanism for VEGFR dimerization and activation, with
homotypic interactions in D5. Mutation of the conserved residues
mediating the D5 interaction (Thr446 and Lys516) and the D7 in-
teraction (Arg737) compromised VEGF-C induced VEGFR-3 activa-
tion. A thermodynamic analysis of VEGFR-3 deletion mutants
showed that D3, D4-5, and D6-7 all contribute to ligand binding.
A structural model of the VEGF-C/VEGFR-3 D1-7 complex derived
from small-angle X-ray scattering data is consistent with the
homotypic interactions in D5 and D7. Taken together, our data
show that ligand-dependent homotypic interactions in D5 and
D7 are essential for VEGFR activation, opening promising possibil-
ities for the design of VEGFR-speciﬁc drugs.
signal transduction | receptor tyrosine kinase
VEGFs stimulate angiogenesis and lymphangiogenesis viaVEGF receptors (VEGFRs) in endothelial cells. VEGF-A sig-
naling is mediated predominantly through activation of VEGFR-2,
resulting in sprouting of blood vessels from preexisting vascula-
ture (1). In contrast, VEGFR-1 seems to have an inhibitory role
by sequestering VEGF-A and thereby preventing its interaction
with VEGFR-2 (2). On the other hand, VEGFR-3 plays an in-
dispensable role in lymphangiogenesis (3). VEGFRs are involved
in various pathological conditions, including solid tumor growth,
tumor metastasis, and vascular retinopathies (4, 5).
VEGF-C and VEGF-D compose a VEGFR-3–speciﬁc subfamily
of VEGFs. They are produced with large N- and C-terminal pro-
peptides and gain activity toward VEGFR-3 and VEGFR-2 on
proteolytic processing (reviewed in ref. 5). VEGFR-3 maturation
involves proteolytic cleavage of the extracellular domain (ECD)
in D5 (6–8). Both VEGF-C and VEGFR-3 also interact with the
coreceptor neuropilin-2 (9). Loss of the Vegfc gene results in em-
bryonic lethality owing to a lack of lymphatic vessel formation (10),
whereas mutations that interfere with VEGFR-3 signaling have
been associated with hereditary lymphedema, andmice deﬁcient in
Vegfr3 die in utero due to abnormal development of the blood vas-
culature (11, 12). VEGFR-3 and its heterodimers with VEGFR-2
are also important for sprouting angiogenesis and vascular network
formation (13–15).
VEGFRs are type V receptor tyrosine kinases (RTKs) com-
posing a family of three transmembrane receptors, with the ECDs
consisting of seven Ig homology domains (D1–D7). For ligand
binding, VEGFRs use predominantly D2, with D3 providing ad-
ditional binding afﬁnity (16–18). In addition, D1 is required for
VEGFR-3 ligand binding, but the exact role of this domain re-
mains elusive (19, 20). VEGFRs and the closely related type III
RTKs are activated by ligand-induced dimerization of the extra-
cellular domain, followed by tyrosine autophosphorylation of the
intracellular kinase domain to generate downstream signaling
(21). As a prototype for these families, crystal structures of the
Mast/stem cell growth factor receptor KIT ECD revealed ligand-
induced homotypic interactions in D4 (22). Electron microscopy
(EM), small-angle X-ray scattering (SAXS), and functional assays
have established that VEGFR-2 D4-7 is essential for receptor
activation by facilitating dimerization through homotypic contacts
formed between D4-5 and D7 (23–26). In line with these ﬁndings,
the crystal structure of a VEGFR-2D7 homodimer reveals a pair of
salt bridges in the juxtaposed loops between strands E and F (E-F
loop), which are dispensable for receptor dimerization but not for
receptor activation (24). Similar mutations in the E-F loop in D4 of
VEGFR-2 do not affect VEGF-A-induced receptor activation (24),
suggesting unique interactions in D4-5.
Blockage of VEGFR function has been shown to inhibit tu-
mor angiogenesis, lymphangiogenesis, and metastasis in several
mouse models (4, 5). Identiﬁed inhibitors include antibodies that
block ligand/receptor binding. We recently reported an antibody
against VEGFR-3 D5 that did not block ligand binding but did
inhibit VEGFR-3 homodimer and VEGFR-3/VEGFR-2 hetero-
dimer formation and signal transduction (8). Similarly, an anti-
body and designed ankyrin repeat proteins (DARPins) targeted
against D4-7 of VEGFR-2 were found to inhibit ligand-induced
receptor activation, but not dimerization (26, 27), suggesting that
such binders represent a new generation of highly speciﬁc inhib-
itors of VEGFR signaling.
In this study, we provide the structural basis of ligand binding
to D1-2 of VEGFR-3 and deﬁne a unique role of D4-5 for
VEGFR dimerization and activation. Using receptor mutants,
we show that homotypic interactions in D5 and D7 are essential
for VEGFR-3 activation. Based on our data, we suggest a gen-
eral mechanism for VEGFR dimerization and activation by li-
gand-induced homotypic interactions in D5 and D7.
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Results
Structure of the VEGF-C/VEGFR-3 D1-2 Complex. We expressed ma-
ture VEGF-C (C137A) and VEGFR-3 D1-2 in insect cells and
crystallized the complex in space group I23 (a, b, c = 166.7 Å).
The complex structure was solved at 4.2-Å resolution by molec-
ular replacement using multiple isomorphous replacement with
anomalous scattering (MIRAS) phases, and was reﬁned to a crys-
tallographic R value of 33.4% and a free R value of 37.1% (Fig. 1
and Table S1). The complex with WT VEGF-C was crystallized in
the same crystal form, and cross-phasing at 6-Å resolution in-
dicated identical packing and complex formation (Fig. S1A).
The overall architecture of the VEGFR-3 complex is very
similar to the previously reported VEGFR-1 (16, 28, 29) and
VEGFR-2 (18, 30) structures except, that in the VEGFR-3
complex structure, D1 is resolved as well. VEGF-C binding is
limited to D2, with D1 protruding away from VEGF-C. Residues
28–134 of D1 are largely disordered, and we could build only the
core of the apparent I-type Ig domain using KIT D1 (PDB ID
code 2E9W) as a model. Our structure conﬁrmed the presence
of a disulﬁde bridge between Cys51 and Cys111 and N-glyco-
sylation of Asn33 and Asn104. Residues 135–224 of D2 repre-
sent a smaller I-type Ig domain with a disulﬁde bridge between
Cys158 and Cys206 and N-glycosylation of Asn166. Confronted
with the low resolution, we could not deﬁne interactions at the
binding interface. The structure clearly shows packing of the
VEGF-C N-terminal helix against strand E and the C/C′ hairpin
loop of D2. To conﬁrm that these interactions are functional, we
generated a double mutant of VEGF-C, D123A/Q130A, for
VEGFR-3 binding studies (Fig. S1B). Our structure shows that
loop 2 (L2) interacts with the loop connecting strands E and F of
D2 and L3 with strands A′ and G.
The VEGF-C/VEGFR-3 D1-2 and VEGF-C/VEGFR-2 D2-3
complex structures can be aligned with an rmsd of 2.1 Å for 336
Cαatoms (Fig. S2 A–C). The N-terminal helix of VEGF-C in the
VEGFR-3 complex is bent ∼9° toward D2, but L1–L3 adopt ap-
proximately the same conformations as in the VEGFR-2 complex.
Structure of VEGFR-3 D4-5.We expressed VEGFR-3 D4-5 in insect
cells and crystallized the puriﬁed protein in space group P3121
(a, b = 133.3 Å; c = 48.9 Å). The structure of D4-5 was de-
termined at 2.5-Å resolution using single isomorphous replace-
ment with anomalous scattering (SIRAS) phases, and was reﬁned
to a crystallographic R value of 21.0% and free R value of 25.3%
(Fig. 1, Table S1, and Fig. S3 A and B).
D4, consisting of residues 330–419, is a small I-type Ig domain.
Structural comparison shows that it is very similar to KIT D4;
both domains can be aligned with an rmsd of 1.6 Å for 82 resi-
dues. However, unique to VEGFR-3 D4, strand D is missing,
and strand C is connected directly to a short strand E on the
opposite side of the molecule. D5, consisting of residues 420–
553, is a larger I-type Ig domain characterized by a single 310
helical turn between strands A and A′, long strands D and E, and
a long C-D loop of approximately 35 residues. Unlike D4, D5 has
low homology to the corresponding D5 of KIT, with an rmsd of
2.6 Å for 74 residues. The overall temperature factor (B-factor)
for D4 is far larger for D4 than for D5 (69.0Å2 vs. 55.1Å2; Fig.
S3C). D4 has no disulﬁde bridges, whereas D5 has a buried
disulﬁde bridge between the two sheets and an exposed disulﬁde
bridge between Cys466 and Cys486 in the C-D loop, in which
proteolytic cleavage occurs between Arg472 and Ser473 (7). The
crystallized VEGFR-3 D4-5 appears to be only partially cleaved
(Fig. S3D). Residues 470–483 in the C-D loop were disordered
and thus were omitted from the ﬁnal model. VEGFR-3 D4-5 has
an overall extended structure connected by the linker peptide,
a salt bridge between Glu344 and Lys539, and a hydrogen bond
between Glu391 and Tyr448 (Fig. S3E).
VEGFR-3 D4-5 Homodimer and Homotypic Interactions in D5. The
D4-5 structure revealed homotypic interactions in D5, covering
a solvent-accessible area of ∼570 Å2 per chain, but not in D4,
where in contrast, Arg378 and Lys387 in the adjacent D4 face
each other, which may lead to domain repulsion (Fig. S3F). The
dimeric D4-5 molecules have a V-shaped arrangement at an angle
of ∼45° and C and N termini at distances of approximately 14 Å
and 65 Å, respectively (Fig. S3 F and G). The homotypic contacts
in D5 between the sheets comprised of strands A′, B, D, and E are
mediated by the helical protrusion between strands A and A′
occupying the cavity between the curved D-E loop and strands A
and A′ in the other chain (Fig. 2A). The interactions are centered
on the fully conserved Thr446 and Lys516, which create hydrogen
bonds with the backbone atoms of Ser430 and Glu428 in strand
A′ of the other chain (Fig. 2 B and C). His425, Glu428, and
Glu509 contribute additional ionic interactions. Val518 and
Ser430, and Thr446 and Ala429 form van der Waals contacts.
The VEGFR-3 D4-5 dimer structure agrees with the archi-
tecture of our previously reported ligand/VEGFR-2 D2-3 com-
plex structures (PDB ID codes 2X1X, 3V6B, and 3V2A).
Superposition of the VEGF-C/VEGFR-2 D2-3 and the VEGF-
C/VEGFR-3 D1-2 structures on the KIT/SCF complex (PDB ID
code 2E9W) creates a model of a VEGF/VEGFR D1-5 complex
(Fig. 1 and Fig. S2C). In this model, the N termini of VEGFR-3
D4 (Asn330) are located within a few Ångstroms of the C termini
of VEGFR-2 D3 (Glu326, the VEGFR-3 Glu329 counterpart).
Homotypic Interactions in D5 and D7 Are Essential for Ligand-Induced
VEGFR-3 Activation. To determine the functional signiﬁcance of the
D5 and D7 interfaces in VEGF-C–induced VEGFR-3 activa-
tion, we generated a D5 double mutant, T446E/K516A (5EA),
a D7 single mutant, R737A (7A) (24), and a D5/D7 triple mu-
tant, T446E/K516A/R726 (5EA7A), of VEGFR-3 (Fig. 3A). To
do so, we expressed WT VEGFR-3 and the mutant constructs
in HEK293 cells and analyzed VEGF-C–induced VEGFR-3
Fig. 1. Crystal structures of the VEGF-C/VEGFR-3 D1-2 complex and the
homodimer of VEGFR-3 D4-5. Shown are surface and cartoon representa-
tions with the two chains of VEGFR-3 in slate blue or yellow and the two
chains of VEGF-C in orange or light orange. The VEGFR-3 complex, the D4-5
homodimer and our previous VEGF-C/VEGFR-2 D2-3 complex (PDB code 2X1X)
were superimposed to the KIT/SCF complex (PDB code 2E9W). VEGFR-2 D3 is
in gray. VEGFR Ig domains 1–5 (D1–D5), VEGF-C loops 1–3 (L1–L3), and the
N-terminal helix (αN) are labeled. Glycan moieties are shown as spheres.








activation using receptor immunoprecipitation, followed by
anti-phosphotyrosine Western blot analysis (Fig. S4A). To
quantify tyrosine autophosphorylation of VEGFR-3, we com-
pared the level of phosphorylation of the band with an apparent
Mr of 120 kDa on Western blots, corrected for VEGFR-3 ex-
pression level. This band represents the fully mature form of the
receptor displayed on the cell surface (Fig. 3B). Our results in-
dicate that the combination of D5 and D7 mutations (5EA7A)
impairs VEGF-C–induced VEGFR-3 activation.
We performed a similar analysis in transfected porcine aortic
endothelial (PAE) cells stably expressing the constructs (Fig. 3C
and Fig. S4B). In these cells, both the D5 double mutant and D7
single mutant demonstrated reduced VEGFR-3 activity; how-
ever, effective VEGFR-3 blocking was obtained only with the
triple mutant 5EA7A, suggesting the mutual importance of D5
and D7 interactions for VEGFR-3 activation.
Membrane-Proximal Domains of VEGFR-3 Provide Increased VEGF-C
Afﬁnity. To explore the effect of the membrane-proximal domains
of VEGFR-3 on VEGF-C binding, we generated C-terminal trun-
cations of the soluble, monomeric VEGFR-3 ECD and measured
VEGF-C binding by isothermal titration calorimetry (ITC). Our
data show thatVEGF-C binding toVEGFR-3 was enthalpically and
entropically favorable, and that the presence of D3 and membrane-
proximal D4-7 increased VEGF-C afﬁnity (Fig. 4). In addition,
deletion of D6-7, D4-5, and D3 gave rise to a gradual increase
in binding enthalpy (ΔH), suggesting that these domains form
additional interactions with the ligand in the case of D3, or ligand-
induced dimerization in the case of D4-7. In addition, theD5mutant
demonstrated decreased afﬁnity and a larger ΔH (Fig. S4 C andD).
SAXS and Single-Particle EM Analysis of the VEGF-C/VEGFR-3 ECD
Complex. To conﬁrm our structural models, we analyzed VEGFR-3
D1-7 and its complex with VEGF-C using multiangle laser light
scattering (MALS) and SAXS (Fig. 5 A and B and Fig. S5 A and B).
Our data show that the VEGFR-3 ECD is monomeric in solution
and that dimerization is ligand-dependent. The SAXS-derived
ab initio model of the complex revealed a bent, T-shaped mo-
lecular envelope, suggesting that the protrusions at the top of
the molecules represent the D1 domains in the ligand-binding
region and the main body represents the dimerized membrane-
proximal domains.
Using the available VEGFR-2 and VEGFR-3 crystal structures
and a homologymodel forD6, we prepared amodel of the dimeric,
glycosylated VEGF-C/VEGFR-3 ECD complex by applying rigid-
body reﬁnement of the SAXS data. The models with the best ﬁt
revealed strong bending in domains D3-5 that would bring VEGF-
C closer to the plasma membrane (Fig. 5 C–E and Fig. S5C).
We also visualized the complex by negative-staining EM. The
data agree with our structural models and clearly identify D1
protruding away from the complex (Fig. 5F and Fig. S6 A and B).
Comparison of selected 2D projections of the D1-5 complex
model with the EM structures also revealed a strong similarity
with ligand-bound D2-5, although the membrane-proximal part
was only partially resolved.
Discussion
Here we present structural data describing ligand binding to
VEGFR-3 and propose a model for receptor activation. The
structural data comprise crystal structures of a VEGF-C/VEGFR-3
D1-2 complex and the VEGFR-3 D4-5 homodimer, as well as an
analysis of the complex by SAXS and EM. Our ﬁndings, com-
plemented by a thermodynamic analysis of VEGF-C binding to
VEGFR-3 and a cellular analysis of receptor constructs speciﬁ-
cally mutated in D5 and D7, clearly show that the VEGFR-3
interactions observed in the crystal structures are functionally
relevant for ligand-mediated dimerization and activation.
The VEGF-C/VEGFR-3 D1-2 complex structure provides a
reliable model of the overall architecture of the ligand–receptor
complex. Comparisons with the VEGFR-1 and VEGFR-2 com-
plex structures show that all three VEGFRs share a conserved
interface in D2 for ligand binding. VEGF-D has an extended
N-terminal helix responsible for high-afﬁnity binding and ac-
tivation of VEGFR-3 (20), and we show here that mutation of
the N-terminal Asp123 and Gln130 of VEGF-C decreases re-
ceptor binding, supporting the idea that the helix is an important
Fig. 2. VEGFR-3 D5 homotypic interactions are centered to the conserved
residues Thr446 and Lys516. (A) Homotypic interactions in D5. The two chains
are shown in cartoon form, color-coded as in Fig. 1. Thr446, Glu509, Lys516,
and their counterparts in strands A and A’ are shown as sticks. Hydrogen
bonds are shown as red dashed lines. (B) D5, with conservation pattern in cyan
through dark red for variable to conserved amino acids. Evolutionary rates of
human,mouse, chicken, andzebraﬁshVEGFR sequenceswerewereplottedusing
the ConSurf Web server. Thr444, Thr446, Glu426, and Lys516 compose a highly
conserved patch on the D5 surface. (C) Representative amino acid sequence
alignment from B. Residues involved in homotypic interactions are colored.
Fig. 3. Homotypic interactions in D5 and D7 are mutually important for
ligand-induced VEGFR-3 activation. (A) Schematic presentation of the WT
VEGFR-3, 5EA, 7A, and 5EA7A mutants of VEGFR-3. (B) Biotinylation of cell
surface-expressed VEGFR-3 isoforms. Biotinylated PAE-VEGFR-3 cell lysates
were immunoprecipitated with streptavidin beads and blotted for VEGFR-3
and HSC70. Total lysates of PAE and PAE-VEGFR-3 cells were used as controls.
(C) PAE cells stably expressing the VEGFR-3 constructs were stimulated with
VEGF-C, and the cell lysates were immunoprecipitated with anti–VEGFR-3
and analyzed for VEGFR-3 autophosphorylation (pY) and expression (R3) by
Western blot analysis. The pY/R3 ratio was quantiﬁed based on the ∼120-
kDa band representing the fully processed VEGFR-3 (6, 7).
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determinant of VEGFR-3 ligand speciﬁcity (Figs. S1B and S4C).
Additional structural elements of VEGF-C, including loops L1,
L2, and L3, are involved in VEGFR-3 binding as well. L1 likely
interacts with D3 (18, 30).
Our data also provide insight into D1. Despite its importance
in VEGFR-3 ligand binding (19, 20), D1 protrudes away from
VEGF-C and has no connections with it. The bent conformation
of the D1-2 module is very similar to that observed in KIT,
platelet-derived growth factor receptor beta, and macrophage
colony-stimulating factor 1 receptor (Fig. S2C) (22, 31, 32). So
far, KIT seems to be the only type III/V RTK that directly uses
D1 for ligand binding (22). D1 may have a positive impact on D2
structural stability, as demonstrated by the poor resolution of the
ﬁrst strand of D2 (βA) in the multiple VEGFR-2 D2-3 struc-
tures, which lack D1 (18, 30). On the other hand, VEGFR-3 D1
has large disordered regions in the ligand complex, suggesting
that it may interact with other binding partners in vivo, such as
neuropilin-2 or the large N- and C-terminal propeptides of
VEGF-C and VEGF-D.
VEGFR-3maturation involves proteolytic cleavage inD5 (6, 7).
This cleavage also occurred in the insect cell-expressed constructs,
although the crystallized D4-5 was mainly uncleaved (Figs. S3D
and S5A). The structure of the VEGFR-3 D4-5 homodimer sug-
gests that proteolytic cleavage did not introduce signiﬁcant
changes in the D5 conformation, because it occurred in the C-D
loop, which is disordered in the Cys466/Cys486 disulﬁde bridge.
This loop is not involved in VEGFR-3 dimerization, leaving the
function of this processing step elusive. Nonetheless, our structure
suggests that the disulﬁde bridge restricts the ﬂexibility of this loop,
thereby increasing the stability of D5.
Calorimetric data for VEGF-C binding to our VEGFR-3 ECD
mutant constructs indicate direct interaction of D3 with the li-
gand. In contrast, the membrane-proximal domains D4-5 and
D6-7 modulate ligand binding indirectly. The contribution of
D4-5 suggests that the homotypic interactions in D5 are ener-
getically favorable. D6-7 does not increase VEGF-C afﬁnity
further; however, the decrease in ΔH indicates additional ho-
motypic receptor contacts. This explains why mutations in D5
and D7 showed an additive inhibitory effect on VEGF-C–stim-
ulated receptor phosphorylation in both HEK293 and PAE cells.
The mutant and the ITC data agree with the observed inter-
actions in D5 and with the putative salt bridges between Arg737
and Asp742 (human VEGFR-3 numbering) in VEGFR-3 D7.
Taken together, the data indicate that the observed homotypic
interactions in the membrane-proximal domains of VEGFRs are
functionally highly relevant, as has been shown previously for
VEGFR-2 (24, 26) and here for D5 and D7 of VEGFR-3.
Fig. 4. Thermodynamic analysis of VEGF-C binding to VEGFR-3. Calorimetric
titrations of VEGF-C to the monomeric VEGFR-3 ECD (D1-7) and its domain
deletion mutants D1-2, D1-3 and D1-5 are shown. The enthalpy change (ΔH),
dissociation constant (Kd), and stoichiometry (N) of the ITC assays are indicated.
Fig. 5. Characterization of the VEGF-C/VEGFR-3 D1-7 complex in solution and in EM. (A) MALS analysis of the VEGF-C/VEGFR-3 D1-7 complex and VEGFR-3
D1-7. (B) The SAXS-derived distance distribution functions and averaged ab initio shape reconstructions of VEGFR-3 D1-7 and the VEGF-C/VEGFR-3 D1-7
complex. (C) Rigid-body models before and after reﬁnement against the SAXS data were aligned using VEGF-C and are shown in cartoon form. The calculated
(red) and experimental scattering curves (black) are compared. (I) The symmetrical model before reﬁnement. (II) A representative model of the reﬁnement
with limited movement: D123C dimer–linker–D45 dimer–linker–D67 dimer. (III) Representative model of the reﬁnement with increased movement: D12C
dimer–linker–D3-D3–linker–D4-D4–linker–D5 dimer–linker–D67 dimer (SI Methods). (D) Rigid-body models from C aligned using the membrane-proximal D6-7
in vertical orientation and shown in a surface representation. (E) Overlay of the ab initio model of the complex from B and the ﬁnal rigid-body model from C.
(F) Representative class averages of the negative stain EM analysis of the VEGF-C/VEGFR-3 ECD complex. (Scale bar: 10 nm.)








VEGFRs are structurally highly similar and also signal as
heterodimers (14, 33). Similar to the conserved D7 interface, the
key residues involved in D5 dimerization (Thr446 and Lys516)
are fully conserved, suggesting that similar D5 interactions exist
in other VEGFRs. D4-directed homotypic interactions have
been suggested previously based on the ligand-induced crossover
in the middle of the EM structure of the VEGF-A/VEGFR-2
ECD complex (23). Considering the low resolution of the 2D
projections of the EM data, these data are compatible with the
involvement of D5 in receptor dimerization, which we report
here for VEGFR-3. A previous binding study indicated that both
D4 and D5 increase the afﬁnity of VEGFR-2 for VEGF-A.
Compared with D1-3, D1-5 showed 86-fold greater afﬁnity and
D1-4 showed 16-fold greater afﬁnity (34). Similarly, both D4 and
D4-5 of VEGFR-1 have been shown to enhance ligand-induced
receptor dimerization in cross-linking experiments (35). Thus,
the results of the VEGFR-1– and VEGFR-2–binding studies
support a role for D5 in VEGFR dimerization, although addi-
tional interactions in D4 cannot be ruled out.
D4 may have an additional functional role, as suggested by
previous studies showing that a swap of D4 with another domain,
but not mutation of the D4 E-F loops facing each other, im-
paired ligand-induced VEGFR-2 activation (24, 26). D4 may
facilitate proper orientation of the ligand-binding D1-3 in the
active complex. D4 in VEGFRs and in type III RTKs lacks the
intradomain disulﬁdes (24), which have been shown to improve
Ig domain stability (36). Compared with D5, the lack of disul-
ﬁdes in VEGFR-3 D4 is reﬂected in the higher overall B-factor
level (Fig. S3C), suggesting increased domain ﬂexibility in D4.
This may be essential for the bending around D3-5 observed in
the SAXS data. D3-4 and D4-5 hinge-like motions were also
observed in the ligand-induced activation of KIT (22).
Based on high-resolution structural data for KIT, a model for
the mechanism of ligand-induced activation of type III/V RTKs
has been proposed (22). With this model, together with the
available structures for VEGFR-2 and VEGFR-3, it is now
possible to construct a similar model for VEGFR activation.
Ligand-induced KIT dimerization promotes reorientation of
D4-5, enabling lateral D4–D4 interactions essential for receptor
activation (22). This seems to be a common mechanism in type
III RTK activation (37–40). Previous studies found similarities in
the ligand-binding modes for type III and IV RTKs and almost
identical homotypic interactions in VEGFR-2 D7 and KIT D4
(18, 24, 32). The VEGFR-3 structures shown here indicate addi-
tional similarities to type III RTKs; however, our results also
demonstrate some unique properties of these receptors that affect
the mechanism of activation.
Despite the lack of homotypic interactions in VEGFR-3 D4,
the arrangement of D4 in KIT and VEGFR-3 dimers is similar,
with the E-F loops facing each other (Fig. S3). KIT D4-5 shows
an almost parallel orientation in the ligand-bound receptor di-
mer, whereas VEGFR-3 D4-5 is twisted, resulting in separation
of D4 and formation of unique D5 interactions (Fig. 6A). Be-
cause VEGFR activation also requires homotypic interactions in
D7, the two additional Ig domains of VEGFRs give rise to
a more complex, two-step mechanism for ligand-induced di-
merization and receptor activation. This may be functionally
relevant by allowing tight control of receptor activation.
The subunit interactions in the D7 homodimer of VEGFR-2
cover a solvent-accessible area of only 480 Å2 per chain, and D7
has been shown to be monomeric in solution, indicating that the
interactions are of low afﬁnity (24). The dimerization interface
in D5 is also relatively small (∼570 Å2 per chain), and the in-
terface is dominated by ionic interactions. Like VEGFR-2 ECD,
VEGFR-3 ECD is monomeric in solution, clearly showing that
D5 and D7 are not capable of dimerizing the receptor in the
absence of ligand (Fig. 5) (25). The restricted mobility of the
receptors in the transmembrane domain may further aid the for-
mation of such contacts in active receptor dimers.
A recent EM study revealed that the VEGFR-2 ECD is ﬂexible
and exists in multiple conformations in ligand-induced dimerization
(23). Similarly, comparison of the available ligand/VEGFR-2 D2-3
complex structures found large variations in the D2-3 twist angles,
indicating a D2-3 hinge-like rigid body motion (18, 30). Taken to-
gether with our data, these ﬁndings suggest a general mechanism
for VEGFR activation in which ligand-induced D2-3 reorientation
facilitates homotypic interactions in D5 and D7, resulting in spe-
ciﬁc positioning of the transmembrane and intracellular kinase
domains in active receptor dimers (Fig. 6B). Interestingly, our SAXS
data revealed strong bending of the receptor ECD complex in so-
lution, which would bring VEGF-C closer to the plasma membrane
when bound to the cell surface-expressed VEGFR-3. This bending,
along with the distorted symmetry of receptor dimers, might be
relevant for coreceptor binding.
VEGFRs also demonstrate differences in ligand-induced acti-
vation. D2 is the major ligand-binding domain, and the presence
of D3 results in increased afﬁnity in VEGF-A binding to VEGFR-
2 and in placental growth factor binding to VEGFR-1 (17, 28).
Consistent with the D2-3 reorientation, VEGFR-3 D3 also in-
creases VEGF-C binding, whereas D4-5 and D6-7 further increase
VEGFR-3 ligand-binding afﬁnity. In contrast, the homotypic
interactions in VEGFR-2 D4-7 are energetically unfavorable (30),
suggesting that D3’s contribution to ligand binding is essential for
VEGFR-2 dimerization and activation. VEGFR-1 D4-7 has only
a small positive effect on ligand binding (16, 28).
VEGFR signaling has emerged as a key target for inhibiting
tumor growth and metastasis by blocking tumor vascularization.
Current therapeutics inhibiting VEGFR signaling include tyro-
sine kinase inhibitors, ligand traps, and antibodies blocking li-
gand binding to VEGFRs (4, 5). However, as is evident from
previous studies, VEGFR and type III RTK activation requires
additional speciﬁc homotypic interactions between the membrane-
proximal domains (22–26, 38). Antibodies blocking these homo-
typic interactions are promising tools for therapeutic modulation of
VEGFR activity (8, 26, 27). The experiments reported herein in-
troduce a mechanism for VEGFR dimerization and activation via
D5 and explain the efﬁcacy of the VEGFR-3 D5-targeted anti-
bodies (8). Our data suggest that the ligand-induced homotypic
interactions in D5 and D7 are essential for VEGFR activation,
providing strategies for the design of speciﬁc VEGFR inhibitors
for use in combination with current anti-angiogenic inhibitors.
Fig. 6. The mechanism of ligand-induced VEGFR dimerization and activation.
(A) Comparison of the ligand-induced dimerization of D1-5 of type III/V RTKs.
The KIT/SCF complex (22) and the model of the VEGFR-3/VEGF-C complex are
shown as surface representations in two orientations. SCF dimer is colored in
magenta and in light magenta, and the two chains of KIT, VEGF-C, and VEGFR-
3 are color-coded as in Fig. 1. (B) A proposed model of the ligand-induced
dimerization and activation of VEGFRs. D1-2 represents the major ligand-
binding unit. Ligand-induced D2-3 reconﬁguration facilitates homotypic inter-
actions in D5 and D7 that together are important for VEGFR activation. SAXS
data indicates bending of the VEGF-C/VEGFR-3 complex around D3-5.
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Such an approach with two HER2 antibodies has proven suc-
cessful in the treatment of patients with HER2-positive meta-
static breast cancer (41).
Methods
Protein Expression and Puriﬁcation. Human VEGF-C, residues 103–215; C137A
mutant of VEGF-C; human VEGFR-3 Ig D1-2, D1-3, D1-5, and D1-7; and the
mutant 5EA in D1-5 were expressed in Sf21 insect cells using the baculovirus
system and puriﬁed as described in SI Methods.
Binding Assays. Calorimetric titrations of VEGF-C (C137A) to the monomeric
VEGFR-3 deletion mutants were performed with a MicroCal VP-ITC calo-
rimeter, as described in SI Methods. The data were processed using Origin
7.0 (MicroCal).
Crystallization and Structure Determination. The VEGF-C/VEGFR3-D12 com-
plex crystals were grown over a reservoir solution of 1.0–1.5 M ammonium
sulfate (pH 8.5–9.5). Heavy-atom derivatives were prepared by soaking the
crystals with methylmercury acetate, potassium tetrachloroplatinate, or hex-
atantalum tetradecabromide. VEGFR-3 D4-5 crystals were grown over a res-
ervoir solution of 20–25% PEG 400 (pH 7.5–8.5), and a heavy-atom derivative
was obtained with methylmercury acetate.
Complete datasets to 4.2-Å and 2.5-Å resolution were collected from the
VEGF-C/VEGFR-3 D1-2 complex and the VEGFR-3 D4-5 crystals, respectively,
at beamline X06SA at the Swiss Light Source (SLS). Anomalous data on the
heavy-atom derivatives were collected at SLS beamlines X06SA and X06DA
(Table S1). The sites were identiﬁed, and the phases were reﬁned using
autoSHARP (42). The structures were reﬁned using PHENIX (43). Crystallo-
graphic details are provided in SI Methods.
SAXS Data Collection and Analysis. The SAXS data were collected at SLS
beamline cSAXS, and the data were processed using the ATSAS program
package (44). The ab initio shape reconstructions were computed using
DAMMIF, and rigid-body modeling was done using SASREF. Details of SAXS
data collection and analysis are provided in SI Methods.
Negative-Staining EM and Image Analysis. For the VEGF-C/VEGFR-3 D1-7
complex, data were acquired using a Philips CM10 transmission electron
microscope equipped with an LaB6 ﬁlament. For projection analysis, 2,916
particles of the complex were selected from 487 images and classiﬁed into
30 classes. The EM analysis is described in detail in SI Methods.
ACKNOWLEDGMENTS. We thank Tapio Tainola and Seppo Kaijalainen for
excellent technical assistance, Dr. John H. Missimer for SAXS data evalution,
and the staff at European Synchrotron Radiation Facility beamline ID29
and staff at Swiss Light Source beamlines X06SA, X06DA, and cSAXS for
assistance and access to their facilities. This work was supported by grants
from the Academy of Finland, the Sigrid Juselius Foundation, the Louis-
Jeantet Foundation, the European Research Council (ERC-2010-AdG-268804-
TX-FACTORS), Swiss National Science Foundation (Grant 31003A-130463),
Oncosuisse (Grant OC2 01200-08-2007), NOVARTIS Stiftung für medizinisch-
biologische Forschung (Grant 10C61), and the Swiss Initiative for Systems
Biology (SystemsX.ch; grant CINA).
1. Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L (2011) Signal transduction by
vascular endothelial growth factor receptors. Biochem J 437(2):169–183.
2. Ferrara N (2004) Vascular endothelial growth factor: Basic science and clinical prog-
ress. Endocr Rev 25(4):581–611.
3. Tammela T, Alitalo K (2010) Lymphangiogenesis: Molecular mechanisms and future
promise. Cell 140(4):460–476.
4. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438(7070):
967–974.
5. Alitalo K (2011) The lymphatic vasculature in disease. Nat Med 17(11):1371–1380.
6. Pajusola K, et al. (1994) Signalling properties of FLT4, a proteolytically processed re-
ceptor tyrosine kinase related to two VEGF receptors. Oncogene 9(12):3545–3555.
7. Lee J, et al. (1996) Vascular endothelial growth factor-related protein: A ligand and speciﬁc
activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA 93(5):1988–1992.
8. Tvorogov D, et al. (2010) Effective suppression of vascular network formation by
combination of antibodies blocking VEGFR ligand binding and receptor dimerization.
Cancer Cell 18(6):630–640.
9. Kärpänen T, et al. (2006) Functional interaction of VEGF-C and VEGF-D with neuro-
pilin receptors. FASEB J 20(9):1462–1472.
10. Kärkkäinen MJ, et al. (2004) Vascular endothelial growth factor C is required for
sprouting of the ﬁrst lymphatic vessels from embryonic veins. Nat Immunol 5(1):
74–80.
11. Kärkkäinen MJ, et al. (2000) Missense mutations interfere with VEGFR-3 signalling in
primary lymphoedema. Nat Genet 25(2):153–159.
12. Dumont DJ, et al. (1998) Cardiovascular failure in mouse embryos deﬁcient in VEGF
receptor-3. Science 282(5390):946–949.
13. Tammela T, et al. (2008) Blocking VEGFR-3 suppresses angiogenic sprouting and
vascular network formation. Nature 454(7204):656–660.
14. Nilsson I, et al. (2010) VEGF receptor 2/-3 heterodimers detected in situ by proximity
ligation on angiogenic sprouts. EMBO J 29(8):1377–1388.
15. Tammela T, et al. (2011) VEGFR-3 controls tip to stalk conversion at vessel fusion sites
by reinforcing Notch signalling. Nat Cell Biol 13(10):1202–1213.
16. Wiesmann C, et al. (1997) Crystal structure at 1.7-Å resolution of VEGF in complex
with domain 2 of the Flt-1 receptor. Cell 91(5):695–704.
17. Fuh G, Li B, Crowley C, Cunningham B, Wells JA (1998) Requirements for binding and
signaling of the kinase domain receptor for vascular endothelial growth factor. J Biol
Chem 273(18):11197–11204.
18. Leppänen VM, et al. (2010) Structural determinants of growth factor binding and
speciﬁcity by VEGF receptor 2. Proc Natl Acad Sci USA 107(6):2425–2430.
19. Jeltsch M, et al. (2006) Vascular endothelial growth factor (VEGF)/VEGF-C mosaic
molecules reveal speciﬁcity determinants and feature novel receptor binding pat-
terns. J Biol Chem 281(17):12187–12195.
20. Leppänen VM, et al. (2011) Structural determinants of vascular endothelial growth
factor-D receptor binding and speciﬁcity. Blood 117(5):1507–1515.
21. Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell
141(7):1117–1134.
22. Yuzawa S, et al. (2007) Structural basis for activation of the receptor tyrosine kinase
KIT by stem cell factor. Cell 130(2):323–334.
23. Ruch C, Skiniotis G, Steinmetz MO, Walz T, Ballmer-Hofer K (2007) Structure of
a VEGF-VEGF receptor complex determined by electron microscopy. Nat Struct Mol
Biol 14(3):249–250.
24. Yang Y, Xie P, Opatowsky Y, Schlessinger J (2010) Direct contacts between extracel-
lular membrane-proximal domains are required for VEGF receptor activation and cell
signaling. Proc Natl Acad Sci USA 107(5):1906–1911.
25. Kisko K, et al. (2011) Structural analysis of vascular endothelial growth factor re-
ceptor-2/ligand complexes by small-angle X-ray solution scattering. FASEB J 25(9):
2980–2986.
26. Hyde CA, et al. (2012) Targeting extracellular domains D4 and D7 of vascular endo-
thelial growth factor receptor 2 reveals allosteric receptor regulatory sites. Mol Cell
Biol 32(19):3802–3813.
27. Kendrew J, et al. (2011) An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits
VEGFR-2 activation and VEGFR-2-dependent angiogenesis without affecting ligand
binding. Mol Cancer Ther 10(5):770–783.
28. Christinger HW, Fuh G, de Vos AM, Wiesmann C (2004) The crystal structure of pla-
cental growth factor in complex with domain 2 of vascular endothelial growth factor
receptor-1. J Biol Chem 279(11):10382–10388.
29. Iyer S, Darley PI, Acharya KR (2010) Structural insights into the binding of vascular
endothelial growth factor-B by VEGFR-1(D2): Recognition and speciﬁcity. J Biol Chem
285(31):23779–23789.
30. Brozzo MS, et al. (2012) Thermodynamic and structural description of allosterically
regulated VEGFR-2 dimerization. Blood 119(7):1781–1788.
31. Chen X, Liu H, Focia PJ, Shim AH, He X (2008) Structure of macrophage colony-
stimulating factor bound to FMS: Diverse signaling assemblies of class III receptor
tyrosine kinases. Proc Natl Acad Sci USA 105(47):18267–18272.
32. Shim AH, et al. (2010) Structures of a platelet-derived growth factor/propeptide
complex and a platelet-derived growth factor/receptor complex. Proc Natl Acad Sci
USA 107(25):11307–11312.
33. Cudmore MJ, et al. (2012) The role of heterodimerization between VEGFR-1 and
VEGFR-2 in the regulation of endothelial cell homeostasis. Nat Commun 3:972.
34. Shinkai A, et al. (1998) Mapping of the sites involved in ligand association and dis-
sociation at the extracellular domain of the kinase insert domain-containing receptor
for vascular endothelial growth factor. J Biol Chem 273(47):31283–31288.
35. Barleon B, et al. (1997) Mapping of the sites for ligand binding and receptor di-
merization at the extracellular domain of the vascular endothelial growth factor
receptor FLT-1. J Biol Chem 272(16):10382–10388.
36. Carl P, Kwok CH, Manderson G, Speicher DW, Discher DE (2001) Forced unfolding
modulated by disulﬁde bonds in the Ig domains of a cell adhesion molecule. Proc Natl
Acad Sci USA 98(4):1565–1570.
37. Verstraete K, et al. (2011) Structural insights into the extracellular assembly of the
hematopoietic Flt3 signaling complex. Blood 118(1):60–68.
38. Yang Y, Yuzawa S, Schlessinger J (2008) Contacts between membrane proximal re-
gions of the PDGF receptor ectodomain are required for receptor activation but not
for receptor dimerization. Proc Natl Acad Sci USA 105(22):7681–7686.
39. Elegheert J, et al. (2011) Extracellular complexes of the hematopoietic human and
mouse CSF-1 receptor are driven by common assembly principles. Structure 19(12):
1762–1772.
40. Ma X, et al. (2012) Structural basis for the dual recognition of helical cytokines IL-34
and CSF-1 by CSF-1R. Structure 20(4):676–687.
41. Swain SM, et al. (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive
metastatic breast cancer (CLEOPATRA study): Overall survival results from a rando-
mised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14(6):461–471.
42. Vonrhein C, Blanc E, Roversi P, Bricogne G (2007) Automated structure solution with
autoSHARP. Methods Mol Biol 364:215–230.
43. Adams PD, et al. (2010) PHENIX: A comprehensive Python-based system for macro-
molecular structure solution. Acta Crystallogr D Biol Crystallogr 66(Pt 2):213–221.
44. Petoukhov MV, Svergun DI (2007) Analysis of X-ray and neutron scattering from bi-
omacromolecular solutions. Curr Opin Struct Biol 17(5):562–571.
Leppänen et al. PNAS | August 6, 2013 | vol. 110 | no. 32 | 12965
BI
O
CH
EM
IS
TR
Y
